alexa The Role Of Regulatory Policies In Relation To The Local Biosimilars Production
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

8th Asian Biologics and Biosimilars Congress
August 10-12, 2017 Beijing, China

Gustavo H Marin
La Plata UNLP-CONICET, Argentina
ScientificTracks Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X-C1-032
Abstract
Biosimilars are medicines that are not original products subject to patents; greatly reduce the cost of treatments. However, if they are subject to the processes of guarantee of efficacy and safety that are requested to the original biotechnological medicines, the costs remarkably increase. This point force countries to face a dilemma, provide access to their population to innovative treatments or avoid the potential adverse effects associated with their use. Biosimilars are increasingly attractive niche to several countries around the world. They are drugs of biotechnological origin, which has proven to be comparable to the innovative drug of reference once its patent has expired, since they are considered therapeutic equivalents in terms of safety and efficacy. However, these data come from very expensive studies such as randomized clinical trials. It is thus that underdeveloped countries like those of Latin America are in a permanent dilemma of either guaranteeing the access to these new products (generally for catastrophic diseases) or taking care of the population of its potential adverse effects. Latin American governments developed different strategies to face biosimilars market. Abbreviated regulatory pathways, alliance between public and private sector, promotion of science agencies benefits to finance part of local industry to develop new biosimilars and transfer of human resources from the academic to the business are some of those strategies. Brazil, Cuba and Argentina are interesting examples to study because their way chose to develop the industry. While Brazil and Cuba has led policies to increase the development of biosimilar drugs based on local public manufacturing capabilities and on relaxed standards regulation and became one of the majors world producers; in Argentina, exists three majors biotechnology private pharmaceutical enterprises that managed the market, articulating with local science and technology infrastructure and receiving governments’ benefits in order to enter into the biosimilars segment. In this last country the Regulatory Administration (ANMAT) did not accompany the promoting policies relaxing the regulatory standards. Through these experiences, it would seem that in order to be successful in the development of the local biosimilars market, it would be necessary to accompany the market’s efforts with flexibilities in regulatory, registration and production standards.
Biography

Gustavo H Marin is the Head Professor in Pharmacology Department of National University of La Plata. He belongs to CONICET research system. He is a Doctorate in Medicine, Master in Public Health, Master in Health Economics and in Political Science. He was a Former Medical Doctor in Public Health Assistance of Paris and Post- Doctoral Foreigner Assistant in University Paris, Diderot, France. He is the main author of more than 150 papers and was the Director of Science Policies of Buenos Aires State in Argentina and Director in health care Ministry of Health. Also, he is the Specialist in Hematology and in Public Management.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]e.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords